FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.677,92 -652,41 (-1,08%)
Eton Pharmaceuticals, Inc. (ETON)
Dopo ore:
| Chiusura precedente | 3,1200 |
| Aperto | 3,1500 |
| Denaro | 2,5600 x 200 |
| Lettera | 4,0300 x 200 |
| Min-Max giorno | 3,1500 - 3,6700 |
| Intervallo di 52 settimane | 2,4200 - 5,8100 |
| Volume | |
| Media Volume | 60.420 |
| Capitalizzazione | 88,624M |
| Beta (5 anni mensile) | 1,18 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0400 |
| Prossima data utili | 11 mar 2024 - 26 mar 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireEton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it has entered into an agreement to
- GlobeNewswire
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Wednesday, September 13, 2023 Time:9:00am ET To schedule a 1x1 meeting with the Company, please contact Corporate Access at
- GlobeNewswire
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine AnhydrousManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today re
